Sontatic gene therapy is a potentially useful strategy for the delivery of growth factors or cytokines to enhance wound healing. Experintental excisional and incisional wounds in impaired-healing diabetic ntice (dbldb) were treated with aFGF and with a plasntid coding for aFGF. A eukaryotic expression plasntid composed of the Hst signal peptide sequence infrante with the human aFGF sequence was used. Transfection of tissues was accontplished either by direct plasmid uptake or by uptake facilitated with cationic liposomes. The results show that the closure of excisional wounds was significantly accelerated (p < 0.05) by topical application of human recontbinant aFGF or by transfection with the aFGF plasmid but not by vehicle or control plasmid not containing the aFGF sequence. In incisional wounds, aFGF or transfection with the plasmid significantly increased A cidic fibroblast growth factor (aFGF or FGF-1) is one of the most promising cytokines for treating impaired wound healing. aFGF is a short polypeptide that influences the general proliferative capacity of a wide range of mesoderm-and neuroectoderm-derived cells ;/1 1/;11'0 and is also a potent angiogenesis inducer ;/1 1/;/10 (Imamura el ai, 1990; Mason, 1994) . In rats and mice, exogenously applied aFGF promoted healing of full-thickness dermal wounds and produced a transient increase of tensile strength in incisional wounds (Mellin et ai, 1992 (Mellin et ai, , 1995 . Applications of aFGF have been limited, however, because of the necessity to administer relatively large amounts of recombinant aFGF that is often blocked fi'om reaching the target tissue by eschar. The short half-life of aFGF is another drawback of topical application that necessitates fi'equent dosing (Gutierrez el ai, 1992) . Frequent application of aFGF with high doses to overcome diffusion problems can be costly.
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Abbreviations: aFGF, acidic fibroblast growth factor; RT-PCR, rcvcrsc transcription-coupled polymerase chain reaction. the wound-breaking strength compared to their corresponding controls (p < 0.05). Quantitative histology of the plasntid-treated incisional wound sections revealed improved wound quality. The transcription of ntRNA from human aFGF cDNA in the incisional wound tissue extracts was confirmed by RT-PCR, and the expressed aFGF was detected by intmune dot blot and immunohistochemistry assays. The transfection was a transient process with a peak at 9 din dbl+ (littermates of the diabetic mice) incisional wounds, at 36 d in dbldb incisional wounds, and at 27 d in dbldb excisional wounds. Cells transfected with human aFGF occupied up to 6.4% of the transectional area in the wound sites. Thus, aFGF gene delivery resulted in both gene expression and a functional improvement in healing. Key words: getle t1lel'apJ,ldiabetic lIlicelcytokitle e~1'ressiotl. ] Il1vest Derlllato [ 108:313-318, 1997 problems. Skin wounds represent an attractive target for therapeutic gene manipulation because wounds are readily accessible. Major skin-cell types (such as fibroblasts, keratinocytes, and endothelial cells) are usually easy to infect with currently used vectors (Krueger el ai, 1994) . Skin cells are highly responsive to the aFGF timulus, and the results are easy to observe (Krueger el 01, 1994). To establish a practical somatic gene therapy for wound healing, this study was designed (i) to use recombinant human aFGF to dem-onsU'ate its therapeutic effect on wounds in genetically healingimpaired diabetic mice, (ii) to apply a plasmid containing an insert of human aFGF cDNA to the wounds and to confirm the ;1/ 1/;1/0 transcription and translation of the aFGF cDNA, and (iii) to determine whether the expressed aFGF can result in a local effect with potential therapeutic significance.
MATERlALS AND METHODS
Construction of the Expression Vector for aFGF Thc plasmid pMEXnco-sp-aFGF, which is composed of thc eDNA for human signal pcptide and human aFGF, was a gift from X. Zhan and T. Maciag, American Red Cross, Rockville, MD (Forough et 01. 1993) . Briefly, an !lSI signal peptide (sp) scquence was joined in-frame at the 5' end of the aFGF cDNA to facilitate the secretion of the peptide, and the full-length cDNA of the sp-aFGF was constructed between the restriction sites of Sail and EcoRl in the plasmid pMEXneo. A Kozak sequence with the initial codon within it preceded the 5' region of the sp-aFGF eDNA for maximal cukaryotic translation efficiency. A sequcnce of murinc sarcoma virus long terminal repeat and a simian virus 40 polyadenylation site werc, rcspectively, located up-and downstream of the insert (Fig 1) • Figure 1 . Construct of pMEXlleo and schematic diagram of the priming site of two primer sets. The signal peptide-aFGF (sp-aFGF) cON A was inserted between tbe SolI and EwRl restriction sites to form pMEXneo-sp-aFGF.
tbe insert was prepared by double digestion witb SoiI/EcoRI. gel purification of the large fi'agment, then blunting, and ligation of tbe ends of the linear plasmids with mung bean nuclease and T4 ligase.
aFGF and aFGF cDNA Delivery to Excisional Wounds The experiments reported berein were conducted according to the principles set forth in tbe Cllide for i"e Core olld Use of LO/JlII'OIOll' Allilllois ('1985) . Genetically bealing-impaired female diabetic mice (8-wk-old C57BLlKsj dlJldb, from The jackson Laboratory, Bar Harbor, ME) that exhibit several characteristics of human adult-onset diabetes, including obesity and markedly delayed wound closure, and arc widely accepted as an ill "i"o model to study wound bealing (Greenhalgh et 01, 1990; Brown et 01, 1994; Sun el 01, 1996) were used to evaluate tbe ill ,Ji"o effect of aFGF and aFGF cDNA. A single full-thickness 6-mm diameter (0.28 cm 2 ) excisiona! wound was made on the mid-dorsum with a biopsy puncb (Acuderm Inc., Ft. Lauderdale, FL) and left undres cd. In each experiment, groups of five animals were treated witb eitber 1.0 J.Lg of buman recombinant aFGF (GIBCO BRL, Gaitbersburg, MD) in J 0 J.LI of pbospbate-buffered saline (PBS) containing 0.3 J.Lg of beparin or tbe PBS vebicle as control once daily for 15 consecutive days after wounding (two experiments). For gene therapy groups, 2.5 J.Lg of pMEXneo-sp-aFGF in 10 J.LI of a Lipofectamine/Dulbecco's modified Eagle's medium (1 :1, vol/vol) mixture witb 0.3 J.Lg of beparin or 2.5 J.Lg of pMEXneo in 10 J.LI of Lipofectamine/Dulbecco's modified Eagle's medium (1 :1) mixture (as a control) were topically applied to tbe wounds once daily for three consecutive days after wounding (five experiments), Scabs were gently removed on days 3, 5, 7, 9. 11, 13, and 15 after wounding to accun'tely visualize the wound margin and to facilitate access of tbe tested reagent to tbe wound. The wound area was recorded and analyzed at 1 b after wounding (day 0), on day 1 and alternate days thereafter by using an image analysis system (BioScan Inc., Edmonds, W A).
Application of aFGF and aFGF Gene to Incisional Wounds The diabetic animals were divided into ten groups of five mice, and a linear incision 2 cm long was made transversely on tbe shaved dorsum and closed by sutures. In the aFGF groups, eacb mouse in two groups of mice received 1.5 J.Lg of buman recombinant aFGF in 15 J.Ll of PBS containing 0.3 J.Lg of heparin once daily for 12 d (5 J.LI topical on incision margins and 10 J.LI injected subcutaneously at tbe base of tbe incision) and another two groups of mice received only PBS containing beparin as control (two experiments).
In the aFGF gene groups, each mouse in tbree groups of mice received 130 J.Lg of pMEXneo-sp-aFGF in 35 J.LI of PBS witb 0.3 !J.g of heparin (5 ILl topical on wound margin and 30 J.LI injected subcutaneously at tbe base of ...
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tbe incision). and each mouse in another three groups received 130 ILg of pMEXneo (as control) once daily for 12 d (three experiments). All groups treated with aFGF or PBS, one group treated witb pMEXneo-sp-aFGF, and one group treated with pMEXneo plasmjd were sacrificed on day 17 after \vollnding. The rClnaining groups \vcrc sacrificed on da)7 27 after wounding.
Tbe wound strip was excised from the dorsal skin and cut into an 8-l1l1n-widc strip by using a tClnplatc. Breaking strength \\1;15 1'11easured immediately after excision by using a custom-made tensiometer. Tension was applied at a constant rate of ' I cm/min by using a 1.0-kg force transducer. Breaking strength, the point of maximal stress before wound separation, was recorded and analyzed on a computer supplied with custom-made software.
To prevent disturbance of wounds by licking. all animals were individually housed after wounding, Reverse Transcription-Coupled Polymerase Chain Reaction (RT-PCR) Assay of the aFGF Gene Transcription To examine the tr:lI1scription of sp-aFGF cDNA in the db/db incision specimens harvested 27 d after wounding, total RNA was extracted from the tissue and digested with RNase-free DNase (GlDCO BRL, Gaithersburg, MD). Then, RT-PCR was performed according to the protocols provided b)' manufacturer (Invitrogen, San Diego, CA). Two primer sets were designed (Fig 1) : primer set 1 for amplifying the full-length human aFGF sequence (sense sequence,S'-ATGGCTGAAGGGGAAATCACCACCTTCACAGCCCT-3'; antisense sequence, 5 'TTAATCAGAAGAGACTGGCAGGGGGAG-AAACAAGA-3') and primer set 2 for the spticed full-length sequence of tbe signal peptide and human aFGF (sense sequence, 5'-GGGAGAC-CGTCTAGATGGCGGGGCCCGGGACGGC-3'; antisense sequence, 5'-GTCGACCTTAAGTTAATCAGAAGAGACTGGCAGGGG-3').
Dot Blot Assay of the Expression Product of the aFGF Gene
The skin margin along the incisional wound treated with pMEXneo-sp-aFGF was harvested, trimmed to about 3 mm in width, chopped into small pieces in a dry ice box. homogenized at 4°C in NaCIITris(hydroxymethyl)aminomethane (Tris) buffer (pH 7.6) in the presence of 100 J.Lg of phenybnetllylsulfonyl fluoride per ml and 2 ILg of aprotinin per ml (Sigma, St. Louis, MO), and centrifuged at 10,000 X g for 20 min. The supernatants were centrifuged with Centricon 100 (Amicon, Danvers, MA) at 1000 X g to remove molecules larger than 100 kDa and then concentrated with a Centricon 3. The skin containing the incision treated with pMEXneo only and a piece of normal skin from each animal were harvested, processed identically, and used as controls 1 and 2. respectively. Immune dot blot wa perfon1led with 3 or 6 ILl of ti,e concentrated filtrate with an equivalent amount of protein (1 ILg/ ILl) loaded on nitrocellulose filters (Millipore, Bedford, MA). The blots were probed with polyclonal antibodies (R & 0 Systems, Minneapolis. MN) against bovine aFGF and developed according to the manuf.,cturer's instructions (Vector Laboratories, Burlingame. CA).
Inlmunohistochel11ical Assay of the Gene Transfection Efficiency and Morphometric Assay of Wound Healing To determine the time course of gene transfection efficiency, the diabetic mice and their lean littermates (C57BL/Ksj diJ/+, The jackson Laboratory, Bar Harbor, ME) were used, A full-thickness excisional or incisional wound was made and treated with pMEXneo-sp-aFGF or pMEXneo as described above. The wound was harvested at the designed intervals, fixed in 10% neutralbuffered formalin for 24 h, embedded in paraffin. and sectioned at 5 J-Lln thickness. After being deparaffinized and rehydrated in water, the sections were digested with 0.1% trypsin for 1 h, blocked with goat nonimmune serum for 20 min, probed witb the primary antibodies. and stained with Fast Red by following the procedures of the manufacturer (Sigma, St. Louis, MO). The tissue sections were observed with a Nikon Optiphot microscope with a color vidco cmTIera connected to an inlage analysis systcnl. Thc ill /li/lo transfection efficiency of the aFGF gene was defined in the following way: under the X40 objective lens, the region of cell transfection adjacent to tbe wound was located and the anti-aFGF stained areas were measured in sample areas by setting the threshold range of the red staining color. The transfected areas were then expressed as percentages of the sampled areas. The value of the transfection efficiency is the mean of measurements from two fields per section of two sections per incision or excision wound from three or four mice in each group. An image analysis system was used to evaluate transectional scar area. cellular density, hair follicle number, and dermal thiclO1ess as measures of tllC quality of wound heaung.
Statistical Analysis Data are presented as means ± SO except where indicated. Statistical analysis of the data were performed by using the one-way analysis of va,;ance test with significance at 0.05 level.
RESULTS
Acceleration of Healing by aFGF or aFGF Gene The exogenous application of aFCIO improved healing of full-thickness skin controls (Fig 3B,D) , Image analysis of the tissue sections revealed that the transfected wounds had a significantly smaller mean transectional scar area, higher cellular density, more hair follicles in the wound sites. and a tendency toward a thinner dermal layer and a more nearly normal complement of fat cells (Table II , Fig 3) .
Transcription of sp-aFGF cDNA I" Vivo The transcription of human aFGF in the incisional wound tissue extracts was demonstrated by RT-PCR using two primer sets. The human aFGF I11.RNA and the sp-aFGF chimeric mRNA were detected ;tI 11;110 (Fig 4, Illites 4 ,5) but only in transfected wounds. Neither the Hst signal peptide nor human aFGF should exist in a mouse. We considered the possibility that the pMEXneo-sp-aFGF plasmid injected into tlle wounds might be can'ied over to the tissue extracts and amplified in the RT-PCR, resultiug in a falsc positive, even though there was a 15-d period betwcen termination of the injection of pMEXneo-sp-aFGF DNA and harvesting of the tissue for the RT-PCR. When peR was performcd in the abscnce of reverse t:ranscriptase, however, therc was no detectable amplification of sequcnces in the tissuc cxtract from pMEXneo-sp-aFGFtreated wounds (Fig 4, Intle 3) , indicating that there was no residual sp-aFGF DNA contamination in the extracts of pMEXneo-sp-aFGF-treated wound tissue.
Translation of sp-aFGF cDNA I" Vivo and the Time Course of Gene Transfection Efficiency Immune dot blots of wound tissue extracts showed a hcavily stained dot in extracts of pMEXneo-sp-a FGF-treated wounds, but little stain in the control (Fig 5) . Immunohistochemistry of transfected wound tissues revealed that transfected cells with red st~lining in the cytoplasm area appeared in distinct clusters of a few cells ( Fig 6) . Cells in the dermis and subcutaneous laycr adjaccllt to the wound were transfected, but cells in distal skin wcre not (Fig 3A,C) . Fibroblasts were the main cell type that expressed human aFGF, and keratinocytes in the basal layer werc occasionally observed with red staining. The image analysis of the tissue sections stained with antibody to aFGF showcd a dclay in observable Days Post-wound excisional wounds. Two effects of aFGF on wound healing were observed in excisional wounds. (i) aFGF enhanced the sealing of the wound edge to the underlying tissue, (ii) aFGF accelerated the rate of closure of the wouuds from days 3 to 15 after wounding with a statistically significant (p < 0.05) improvement at day 9 and thereafter until closure was achieved (Table I ). In incisionaJ wounds, a significant (p < 0.05, compared to controls) increase of wound-breaking strength was observed in skin wounds treated with aFGF and harvested at day 17 after wounding (Fig 2) . Thus, aFGF was an effective healing enhancer. The excisional wounds treated with pMEXneo-sp-aFGF showed an accelerated healing at days 13 and 15 after wounding (p < 0.05) compared to controls (Table I) . lncisional wounds treated with pMEXneo-sp-aFGF had a significant increase in breaking strength in the wounds harvested at day 27 after wounding (p < 0.05) but not in the tissue strips harvested at day '17 after wounding when compared to their corresponding controls (Fig 2) . The histology of the excisional and incisional wounds treated with pMEXneo-sp-aFGF and harvested at day 27 after wounding revealed a well-differentiated dermis with many hair follicles (Fig 3A,C) compared with their corresponding increased transfection to a peak that depended on the strain of mouse (Table III) . The incision wounds of diabetic mice achieved the highest mean transfection percentage, 6.4% of the sampled area at 36 d.
DISCUSSION
aFGF eDNA Mitnicked the Effect of aFGF Peptide on Wound Healing Delivery of the pMEXneo-sp-aFGF plasmid to wounds led to the transcription and translation of the human aFGF gene and, most importantly, promoted excisional and incisional wound healing by the criteria of wound area, wound strength, and histology similar to the effect of recombinant human aPGF on healing. The improvement in scar area, cellular density, and hair folHcle numbers suggests a relationship between acceleration of wound remodeling and improvement of the quality of wound healing in pMEXneo-sp-aFGF-treated wounds. This study and the reports of Mellin and colleagues (Mellin et ai, 1992 (Mellin et ai, , 1995 show that recombinant aFGF improves skin healing in mice or rats. The effect in both rats and mice may result from the strong mitogenic effect ofaFGF i/l. vivo (Dabin and Courtois, 1991; Fitzpatrick et ai, 1992; Matuszewska et ai, 1994) and ill lIitro (Chen et ai, 1991· Klein-Soyer ef ai, 1992 Tsuboi et ai, 1992) . Basic FGF, which has skin extracts amplified with primer set 1 (directed to the aFGF sequence); lalle 2, extracts of wounds treated with the control pMEXneo and amplified with primer set 1; lalle 3, tissue extract of the wounds treated with pMEXneo-sp-aFGF and amplificd with primer set 1 but without reverse transcriptase; Imle 4, tissuc extract of the wounds treatcd with pMEXneosp-aFGF and amplified with primer set 2 (directed to the sp-aFGF fusion sequence); lalle 5, tissue extract of the wounds treated with pMEXneo-sp-aFGF and ampl.ified with primer set 1; lalle 6, DNA size ladder. 60% sequence homology with aFGF and shares the capacity to stimulate proliferation in endothelial cells and fibroblasts, improved healing in diabetic mice (Greenhalgh et aI, 1990; Tsuboi and Rifkin, 1990) . The healing process in inlpaired-healing diabetic mice is complex and responsive to many different cytokines (Greenhalgh et aI, 1990; Roemar and Friedmann, 1992; Brown et aI, 1994) , perhaps acting in a concerted temporal and spatial network. The natural structure of the aFGF gene translation product does not possess a classical secretory signal sequence (Burgess et 01, 1986) , and in recent years there has been considerable debate concerning its ability to be secreted at all. Current opinion, however, is moving away from the idea that this molecule is only released from the cell when the integrity of the plasma membrane is compromised, as evidence is accumulating to suggest that it is released from the cell by novel secretory mechanisms Oackson ef aI, 1992; Mignatti et ai, 1992; Mason, 1994) . Because the ability of aFGF to be secreted cannot be simply predicted, we used, in tlus study, a plasmid with the insert of the full-length aFGF sequence and a signal peptide sequence joined in-frame at the 5' end of the aFGF fragment. The transformation of cells ill vitm induced by pMEXneo-sp-aFGF in tlus study (data not shown) and in the work ofForough and colleagues (Forough et 01,1993) demonstrated tllat a secretable form of aFGF was expressed in cell culture, which provided biochemical evidence to explain the acceleration of wound closure and the increase in breaking strength il/. IIivo. It has been hypothesized that impaired wound healing may result from lack of adequate stimulation by growth mctors. In fact, growth factors have been used in clinical n;als to test whether they can improve wound closure in patients with chrOJuc nonhealing wounds (Brown ef ai, 1991; Robson et aI, 1992; Steed et ai, 1992) . Cytokine gene therapy may overcome some of tile shortcomings of direct application of the growth factors. For example, gene therapy encourages a continual supply of growtll factor that is well dispersed within the wound site. That steady synthesis declines as tile wound matures. Also, the gene product would be glycosylated by host glycosylases and dispersed deep into the wound tissue, rather than superficially. Particle-mediated transfection of hum3.ll epidermal growth factor into porcine skin wound cells led to epidennal growth factor tr3.llSCriptiOl1 and translation in the wound and resulted in a significant reduction in leaching of protein into wound fluid, a measure ofreepithelialization (Andree et 01, 1994) . Cytokine gene delivery into living animals has been shown to produce specific systemic inlmunologic effects (Raz et ai, 1993; Wang et 01, 1993) , to induce antitumoral activity (Colombo et 01,1991) , 3.Ild to modify neuronal physiology (Federoff et 01, 1992) . Gene expression in muscle tissue after irljection of plasnud cDNA has been demonstrated in expermlents using reporter gene constructs (Wolff et ai, 1990; Barr and Leiden, 1991; Danko et 01, 1994) . Thus, transfection with genes tailored to a specific healing deficit may permit improvement of healing impaired by that deficiency, such as insufficient vascularization or inadequate keratinocyte proliferation.
Technical Aspects of Gene Therapy for Wound Healing Based on the characteristics of impaired-healing or nonhealing wounds, the strategy for application of somatic gene therapy to wound healing may differ from that currently used for therapy of cancer or inbom errors of metabolism (Anderson, 1992; Roemer and Friedmann, 1992; Greenhalgh et 01, 1994; Krueger et ai, 1994) .
Plasmids as a vector have substantial adv3.lltages for gene delivery for wound healing. The plasnuds are easy to manipulate, C3.l1 accept large inserted sequences, and can be produced stably and cheaply to a lugh level of purity. By comparison, tbe vectors derived from retroviruses or adenoviruses are not recommended in woundhealing management because of potential contamination of replication-competent wild-type virus in the stock of replicationdefective recombinant virus, tile integration of we transferred gene into the host genome, and a potential insertional mutagenesis that may trigger cell tr3.llsformation or even neoplasia (Anderson, 1992; Gutierrez et 01; 1992; Mulligan, 1993; Vile and Russell, 1994) . In tlus study, the transfection efficiency obtained from the incisional wounds indicated that even without selection pressure or any agent to facilitate the transfection, plasmids injected directly to the wowld tissue resulted in not only a cell transfection ill villo but also an effective biologic response.
Sinlplicity should also be considered as an inlportant component of the stl·ategy. For example, topical application or injection of the expression plasmid directing the synthesis of the desired cytokine will obviate the need to express, purify, and administer the recombinant cytokine protein. Likewise, simple injection of the plasmid is more easily adapted to clinical use than alternative mcthods that might rely on stability of a virus vector or of a eukaryotic cell graft. The results of this study showed that either topical application or injection arc effective and practical as gene delivery methods.
In the ideal case, the expression of the applied gene should be limited to the time required for the wound to hcal. This goal may be reached in two ways: by using plasmid or by using heterologous (or modified) genes. Once transfected into mammalian cells, plasmids will remain extrachromosomal as non replicating episomes. The plasmids will be passed to daughter cells at cell division, diluted after repeatcd mitoses of the transfected wound cells, and eventually lost. A weak immune response may eventually inactivate the xenogeneic gene expression and remove the cells expressing the gene product. The histology of the transfected wounds revealed that the highest level of exprcssion of human aFGF was located in the normal tissue adjacent to the wounds rather than the rapidly growing wound tissue itself (see Fig 3) . This observation suggests that the cells in the middle of the wounds proliferated after the pMEXneo-sp-aFGF sequence had been deleted, consistent with the decrease in the number of the transfected cells. In addition, the transfection process was transient, with a slow start and an eventual decline, regardless of the strain of micc, wound type, doses of the aFGF cDNA, and delivery method.
The prospect of genetic manipulation to effect a curc is controversial but may have advantagcs in specific situations such as chronic human wounds or inadequate patient compliance. The cnhancement of healing ill these animal models should encourage further investigation for eventual clinical application.
NOTE ADDED IN PROOF
A reccnt report found that transfcction of murine wounds with pMEX-ncosp-aFGF incrcascd ill vivo keratinoc)'tc proliferation in thc wound sitc as measured immuI1ohistochemically aftcr incorporation of broll1odeoKyuridinc (Xu L, Sun L, Harmon JW, and Nielscn TB: Transfcction of murinc cutaneous wounds with aFGF Plasmid. SIII;r:iwl FOI'I//II XLVII: 699-702. 1996) . This obscrvation suggcstS that a part of thc mcchanism of acrion of thc plasmid ma)' bc stimlllation of cpitheliaUzation of the wOllnd. 
